CL2014000082A1 - Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus. - Google Patents

Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.

Info

Publication number: CL2014000082A1
Authority: CL; Chile
Prior art keywords: vlp; vaccine; virus; particles; human
Prior art date: 2011-07-11

Application number

CL2014000082A

Other languages

English (en)

Inventor

Charles Richardson

Robert F Bargatze

Paul M Mendelman

Original Assignee

Takeda Vaccines Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-11

Filing date

2014-01-10

Publication date

2014-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-10 Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc

2014-07-04 Publication of CL2014000082A1 publication Critical patent/CL2014000082A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

CL2014000082A 2011-07-11 2014-01-10 Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus. CL2014000082A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161506447P	2011-07-11	2011-07-11

Publications (1)

Publication Number	Publication Date
CL2014000082A1 true CL2014000082A1 (es)	2014-07-04

Family

ID=47506489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000082A CL2014000082A1 (es)	2011-07-11	2014-01-10	Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.

Country Status (29)

Country	Link
US (5)	US9801934B2 (es)
EP (3)	EP2731621B1 (es)
JP (2)	JP6208659B2 (es)
KR (1)	KR102096937B1 (es)
CN (3)	CN108567975A (es)
AU (2)	AU2012282658B2 (es)
BR (1)	BR112014000656A2 (es)
CA (1)	CA2841356C (es)
CL (1)	CL2014000082A1 (es)
CR (2)	CR20190540A (es)
DK (1)	DK3299030T3 (es)
DO (2)	DOP2014000004A (es)
EA (3)	EA035442B1 (es)
EC (1)	ECSP14013201A (es)
ES (2)	ES2656527T3 (es)
GE (1)	GEP201706668B (es)
HK (2)	HK1199202A1 (es)
IL (1)	IL230356B (es)
MA (1)	MA35414B1 (es)
MX (2)	MX379496B (es)
MY (1)	MY170746A (es)
PE (1)	PE20140845A1 (es)
PH (3)	PH12021551773A1 (es)
PL (2)	PL2731621T3 (es)
SG (1)	SG10201605644WA (es)
TN (1)	TN2014000008A1 (es)
UA (1)	UA117732C2 (es)
WO (1)	WO2013009849A1 (es)
ZA (2)	ZA201401012B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5476544B2 (ja)	2006-09-29	2014-04-23	タケダワクチン，インコーポレイテッド	ノロウイルスワクチン製剤
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
KR20150129042A (ko)	2007-09-18	2015-11-18	다케다 백신즈 인코포레이티드	노로바이러스에 대한 보호면역반응을 제공하는 방법
EP2731621B1 (en)	2011-07-11	2017-11-01	Takeda Vaccines, Inc.	Parenteral norovirus vaccine formulations
AU2014329403B2 (en)	2013-10-03	2020-10-08	Takeda Vaccines, Inc.	Methods of detection and removal of rhabdoviruses from cell lines
JP6556632B2 (ja)	2013-12-16	2019-08-07	武田薬品工業株式会社	マイクロニードル
CN107184970A (zh) *	2017-02-16	2017-09-22	北京生物制品研究所有限责任公司	口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en)	2017-03-07	2017-04-19	Elopak As	Improvements in or relating to toller mounting arrangements
WO2018210804A1 (en) *	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
WO2019158653A1 (en) *	2018-02-15	2019-08-22	Icon Genetics Gmbh	Immunogenic composition and vaccine for generating an immune response to norovirus
WO2019231712A1 (en) *	2018-05-29	2019-12-05	Stc.Unm	Virus-like particle compositions and methods of using same
CN109265542B (zh) *	2018-09-27	2021-06-15	国药中生生物技术研究院有限公司	特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) *	2018-12-20	2021-08-04	Takeda Vaccines Inc	Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en)	2020-01-08	2021-07-15	Bharat Biotech International Limited	Viral vaccine compositions and methods of preparations thereof
WO2022210742A1 (ja)	2021-03-29	2022-10-06	デンカ株式会社	ノロウイルス由来のペプチド、ポリヌクレオチド、抗体、組成物、ノロウイルスの中和エピトープを同定する方法
EP4340874A1 (en)	2021-05-21	2024-03-27	Takeda Vaccines, Inc.	Solid composition, freeze-drying method and glass vial
CN118252924A (zh) *	2022-12-27	2024-06-28	远大赛威信生命科学(南京)有限公司	用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) *	2023-10-12	2025-04-17	Chengdu Kanghua Biological Products Co., Ltd.	Method of preparing norovirus vaccine without adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6572862B1 (en)	1989-11-08	2003-06-03	Baylor College Of Medicine	Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en)	1991-03-25	1992-10-01	Genelabs Incorporated	NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
WO1993021325A1 (en)	1992-04-08	1993-10-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Wild-type measles virus glycoproteins: vaccine and detection method therefor
AU4851493A (en)	1992-09-07	1994-03-29	Baylor College Of Medicine	Methods and reagents to detect and characterize norwalk and related viruses
JP4028593B2 (ja)	1993-03-23	2007-12-26	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
US5788970A (en)	1994-03-29	1998-08-04	The University Of Maryland College Park	Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CZ336696A3 (en)	1994-05-16	1997-07-16	Merck & Co Inc	Isolated and purified proteins of papillomavirus and process for preparing thereof
US5645051A (en)	1995-04-21	1997-07-08	Dura Pharmaceuticals, Inc.	Unit dose dry powder inhaler
US5861241A (en)	1995-08-16	1999-01-19	University Of Massachusetts	Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en)	1995-12-07	1996-02-07	Danbiosyst Uk	Vaccine compositions
US5834015A (en) *	1996-09-11	1998-11-10	Albany Medical College	Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en)	1996-10-10	1999-09-14	Incyte Pharmaceuticals, Inc.	Project-based full-length biomolecular sequence database
US6491919B2 (en)	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
JP4598201B2 (ja)	1997-04-08	2010-12-15	メルク・シャープ・エンド・ドーム・コーポレイション	安定化ヒトパピローマウイルス製剤
EP0980257A1 (en)	1997-05-01	2000-02-23	Chiron Corporation	Use of virus-like particles as adjuvants
US20040265377A1 (en)	1997-10-27	2004-12-30	Harry Seager	Solid dispersing vaccine composition for oral delivery
WO2000009671A1 (en)	1998-08-14	2000-02-24	Merck & Co., Inc.	Process for purifying human papillomavirus virus-like particles
ES2262359T3 (es)	1998-12-17	2006-11-16	MERCK & CO., INC.	Particulas tipo virus sinteticas con epitores heterologos.
CA2361837C (en) *	1999-02-05	2011-06-07	Merck And Co., Inc.	Human papilloma virus vaccine formulations
KR100771402B1 (ko)	1999-06-22	2007-10-30	국립감염증연구소장이 대표하는 일본국	Ｓｒｓｖ 검출 킷트
JP2002020399A (ja)	2000-07-10	2002-01-23	Osaka Prefecture	ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
WO2003068163A2 (en)	2002-02-14	2003-08-21	Novavax, Inc.	Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
AU2003247337B2 (en)	2002-04-11	2007-09-06	Medimmune, Llc	Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
CA2486118A1 (en)	2002-06-07	2003-12-18	Large Scale Biology Corporation	Flexible vaccine assembly and vaccine delivery platform
PL375306A1 (en)	2002-06-20	2005-11-28	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
CA2514667C (en)	2003-01-30	2013-01-08	Chiron Corporation	Adjuvanted influenza vaccine
WO2004073652A2 (en)	2003-02-20	2004-09-02	Becton Dickinson And Company	Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en)	2003-07-21	2005-04-14	Boyce Thompson Institute For Plant Research, Inc.	Vectors and methods for immunization against norwalk virus using transgenic plants
US20050152911A1 (en)	2003-09-24	2005-07-14	Montana State University	Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en)	2003-10-15	2005-04-28	Brigham And Women's Hospital, Inc.	Methods and compositions for immunomodulation
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
FR2863890B1 (fr)	2003-12-19	2006-03-24	Aventis Pasteur	Composition immunostimulante
US7481997B1 (en)	2004-02-12	2009-01-27	Montana State University	Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en)	2004-05-18	2005-11-24	Goldberg Joanna B	Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es)	2004-09-03	2010-02-23	Ct Ingenieria Genetica Biotech	Composición vacunal contra el virus de la hepatitis c
EA015907B1 (ru)	2004-10-20	2011-12-30	Санофи Пастер Байолоджикс Ко.	Рекомбинантный флавивирус и его применение
GB0428394D0 (en)	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
EP1846028A4 (en)	2005-01-05	2010-06-30	Philadelphia Health & Educatio	TRANSPORT, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
EP1846439A2 (en)	2005-01-31	2007-10-24	The Johns Hopkins University	Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2006091517A2 (en)	2005-02-18	2006-08-31	Novartis Vaccines And Diagnostics Inc.	Immunogens from uropathogenic escherichia coli
WO2006097530A2 (en)	2005-03-18	2006-09-21	Cytos Biotechnology Ag	Cat allergen fusion proteins and uses thereof
CA2608515A1 (en)	2005-06-01	2007-05-10	Dow Global Technolgies Inc.	Production of multivalent virus like particles
EP1736538A1 (en)	2005-06-21	2006-12-27	Cytos Biotechnology AG	Process for the preparative purification of virus-like-particles (VLPs)
US7527801B2 (en)	2005-11-22	2009-05-05	Novartis Vaccines And Diagnostics, Inc.	Norovirus and Sapovirus antigens
JP2007145775A (ja)	2005-11-29	2007-06-14	Falco Life Science:Kk	ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) *	2006-08-02	2008-02-07	Courtoy Nv	Rotary tablet press
JP5476544B2 (ja)	2006-09-29	2014-04-23	タケダワクチン，インコーポレイテッド	ノロウイルスワクチン製剤
PL2121011T3 (pl)	2006-12-06	2014-10-31	Novartis Ag	Szczepionki zawierające antygeny czterech szczepów wirusa grypy
PL2134360T3 (pl) *	2007-03-14	2016-05-31	Takeda Vaccines Inc	Oczyszczanie cząstek wirusopodobnych
AU2008299589B2 (en)	2007-09-12	2014-06-26	Australian Centre For Plant Functional Genomics Pty Ltd	Plant seed active transcriptional control sequences
KR20150129042A (ko) *	2007-09-18	2015-11-18	다케다 백신즈 인코포레이티드	노로바이러스에 대한 보호면역반응을 제공하는 방법
US20100266636A1 (en) *	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
CN102177233B (zh) *	2008-08-08	2015-04-15	莱戈赛特医药股份有限公司	用于增强交叉反应性的包含复合衣壳氨基酸序列的病毒样颗粒
CA2750321A1 (en) *	2009-01-22	2010-07-29	Pharmathene, Inc.	Stable vaccine compositions and methods of use
ES2552383T3 (es) *	2009-02-10	2015-11-27	Novartis Ag	Regímenes de vacuna de la gripe para cepas asociadas a pandemias
US20110070260A1 (en)	2009-09-09	2011-03-24	Baric Ralph S	Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
AU2011207355B2 (en)	2010-01-21	2015-04-02	Takeda Vaccines, Inc.	Targeted heterologous antigen presentation on Calicivirus virus-like particles
AU2011258171B2 (en) *	2010-05-26	2016-11-24	Selecta Biosciences, Inc.	Synthetic nanocarrier combination vaccines
EP2731621B1 (en)	2011-07-11	2017-11-01	Takeda Vaccines, Inc.	Parenteral norovirus vaccine formulations
JOP20130186B1 (ar)	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات
CN112972492B (zh)	2015-12-16	2024-11-08	沃尔特及伊莱萨霍尔医学研究院	Nk细胞中对细胞因子诱导的sh2蛋白的抑制
GB2605883B (en)	2016-10-18	2023-03-15	Univ Minnesota	Tumor infiltrating lymphocytes and methods of therapy
US20210230548A1 (en)	2018-05-03	2021-07-29	Board Of Regents, The University Of Texas System	Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021534074A (ja)	2018-08-20	2021-12-09	タケダワクチン, インコーポレイテッドTakeda Vaccines, Inc.	Ｖｌｐ製剤
AR117462A1 (es)	2018-12-20	2021-08-04	Takeda Vaccines Inc	Vacuna contra norovirus, formulaciones y métodos
CN113518821A (zh)	2019-02-15	2021-10-19	爱迪塔斯医药公司	用于免疫疗法的经修饰的自然杀伤(nk)细胞

2012
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active Active
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 MX MX2018006816A patent/MX379496B/es unknown
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en active Application Filing
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 HK HK14112697.5A patent/HK1199202A1/xx unknown
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 PH PH1/2021/551773A patent/PH12021551773A1/en unknown
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 PH PH1/2014/500093A patent/PH12014500093A1/en unknown
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
2014
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending

Also Published As

Publication number	Publication date
HK1198136A1 (en)	2015-03-13
BR112014000656A2 (pt)	2017-02-14
EA202090699A3 (ru)	2020-11-30
NZ620865A (en)	2015-08-28
NZ710919A (en)	2017-12-22
CA2841356A1 (en)	2013-01-17
US9867876B2 (en)	2018-01-16
PH12014500093A1 (en)	2014-03-17
ES2656527T3 (es)	2018-02-27
MY170746A (en)	2019-08-27
US20210085778A1 (en)	2021-03-25
IL230356B (en)	2019-05-30
DOP2022000030A (es)	2022-06-30
EP2731621B1 (en)	2017-11-01
EP3299030B1 (en)	2022-06-08
EP4112074A1 (en)	2023-01-04
ZA201401012B (en)	2015-05-27
EP2731621A4 (en)	2015-03-25
DK3299030T3 (da)	2022-09-05
PH12021551773A1 (en)	2022-08-01
TN2014000008A1 (en)	2015-07-01
PE20140845A1 (es)	2014-08-03
MX2014000411A (es)	2014-08-26
PH12018501515B1 (en)	2022-02-18
AU2012282658A1 (en)	2013-03-14
US20180185468A1 (en)	2018-07-05
EA201792407A3 (ru)	2018-07-31
US20130273102A1 (en)	2013-10-17
KR102096937B1 (ko)	2020-04-03
EA202090699A2 (ru)	2020-07-31
CN108567975A (zh)	2018-09-25
GEP201706668B (en)	2017-05-25
PL2731621T3 (pl)	2018-10-31
MA35414B1 (fr)	2014-09-01
KR20140066160A (ko)	2014-05-30
CR20140069A (es)	2014-06-27
CR20190540A (es)	2022-04-04
EP2731621A1 (en)	2014-05-21
EA201490258A1 (ru)	2014-05-30
EP3299030A1 (en)	2018-03-28
MX379496B (es)	2025-03-11
SG10201605644WA (en)	2016-09-29
JP2014520852A (ja)	2014-08-25
CN103874507A (zh)	2014-06-18
US11701420B2 (en)	2023-07-18
HK1215154A1 (zh)	2016-08-19
AU2012282658B2 (en)	2014-11-27
WO2013009849A1 (en)	2013-01-17
JP6208659B2 (ja)	2017-10-04
DOP2014000004A (es)	2014-10-31
EA029470B1 (ru)	2018-03-30
US20160000899A1 (en)	2016-01-07
JP2017214357A (ja)	2017-12-07
CA2841356C (en)	2022-03-01
JP6613259B2 (ja)	2019-11-27
EA035442B1 (ru)	2020-06-17
AU2015200836A1 (en)	2015-03-12
US20230338503A1 (en)	2023-10-26
PL3299030T3 (pl)	2022-12-05
HK1199202A1 (en)	2015-06-26
PH12018501515A1 (en)	2019-02-04
ZA201500915B (en)	2016-06-29
AU2015200836B2 (en)	2016-08-25
CN105031637A (zh)	2015-11-11
ECSP14013201A (es)	2014-05-31
US9801934B2 (en)	2017-10-31
ES2926487T3 (es)	2022-10-26
EA201792407A2 (ru)	2018-03-30
UA117732C2 (uk)	2018-09-25
US10675341B2 (en)	2020-06-09
MX356586B (es)	2018-06-05

Publication	Publication Date	Title
CL2014000082A1 (es)	2014-07-04	Metodo para generar inmunidad protectora contra los norovirus en un ser humano mediante la administracion via parenteral de una unica dosis de una vacuna que comprende particulas tipo virus (vlp) del genogrupo i o ii de norovirus.
MX383065B (es)	2025-03-13	Mutantes de virus de influenza y usos para los mismos.
CO2017004119A2 (es)	2017-09-20	Partículas tipo virus modificadas de cmv
CL2014001110A1 (es)	2014-08-22	Compuestos derivados de piperazin-piridin-bifenil-imidazol-pirrolidinas sustituidas, inhibidores de la replicacion del virus de la hepatitis c (hcv); composicion farmaceutica que los comprende; proceso para preparar un compuesto; metodo para tratar una infeccion del virus hcv; y uso para tratar una infeccion del virus hcv.
CR20140189S (es)	2014-09-24	Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
MX2012009581A (es)	2013-01-29	Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
CL2014000245A1 (es)	2014-08-18	Compuestos derivados de heterociclos nitrogenados, inhibidores de replicacion de los virus de influenza; metodo de preparacion; composicionn farmaceutica; metodo para inhibir la replicacion del virus de la influenza en una muestra biológica o un paciente.
EP2547770A4 (en)	2013-10-16	WAXED CHIMERIC CHIMERIC PORCINES CIRCOVIRUS VACCINE
EP3344290A4 (en)	2019-02-27	VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
IL229307A0 (en)	2014-01-30	Inactivated dengue virus vaccine
BR112014010545A2 (pt)	2017-05-02	composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
BR112014001049A2 (pt)	2017-02-21	método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
MX2013013801A (es)	2013-12-16	Oligodesoxinucleotidos inmunoestimuladores.
MX2016016746A (es)	2017-07-11	Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX388525B (es)	2025-03-20	Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.
WO2013033496A3 (en)	2013-04-25	Laser adjuvants for enhancing immune response
CL2014003012A1 (es)	2015-07-10	Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
BR112012016048A2 (pt)	2019-09-24	"exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
DK201370530A (en)	2013-09-23	Salmonid alphavirus vaccine
BR112015019619A2 (pt)	2017-07-18	métodos para liberação e para purificação de partículas tipo vírus expressadas por baculovírus de vírus não encapsulados
CL2015000037A1 (es)	2015-07-31	Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.
CR20150246A (es)	2015-08-14	Composición inmunogénica contra la aeromonas hydrophila
CU20150019A7 (es)	2015-09-29	Rotavirus humanos modificados
MX2018006500A (es)	2019-02-26	Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos.
ES1141483Y (es)	2015-10-07	Aparato para la preparación de infusiones de café, u otra sustancia, mediante vaina o capsula de una dosis, por microondas